Clinical trial
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary…
NCT00030446 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00030446 |
|---|---|
| Title | Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Official title | A Phase II Study Of OSI-774 (NSC 718781) Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, erlotinib hydrochloride |
| Enrollment | 50 |
| Start date | Jan 10, 2002 |
| Primary completion | Feb 11, 2005 |
| Completion | Dec 21, 2009 |
| First posted | Jun 27, 2003 |
| Last update posted | Apr 8, 2020 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: